Testing Glialia for persistent dizziness after COVID
Part of Brain & nervous system clinical trials.
This trial tests a supplement called Glialia for people with persistent dizziness. It compares Glialia to a placebo (inactive pill) in people who have had COVID or not, to see if it helps reduce dizziness symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have been diagnosed with persistent postural perceptual dizziness (PPPD)
- You have recovered from COVID-19 or never had it
- You do not have other brain or ear disorders
- You are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a gentle, non-invasive nerve stimulation in the ear can help reduce chronic dizziness. It is for people with a specific type of dizziness called PPPD that has lasted at least 3 months.
This study looks at a type of long-lasting dizziness called persistent postural-perceptual dizziness, which can happen after a bout of dizziness or balance problems. The goal is to better understand how common it is and how doctors can accurately recognize it, which may lead to better support and treatment.
This trial tests a new physical therapy program for people with persistent postural-perceptual dizziness (PPPD), a condition where dizziness is triggered by standing or moving. The program aims to reduce dizziness and improve daily function.
This Phase 2 trial tests DAOIB to improve “brain fog” and thinking problems that happen after COVID-19. You may be screened if your symptoms started after a COVID infection and have lasted for months, and if your health tests are normal.
This trial tests whether a structured “vestibular perceptual learning” program can improve balance and your body’s balance signals. It may help people who have balance or dizziness challenges by measuring changes after training.
This study tests whether a drug called pembrolizumab, which helps the immune system, can reduce long-lasting nervous system symptoms from COVID-19 (often called long COVID). It is for people who have had symptoms like fatigue, brain fog, or dizziness for at least 6 months after a mild or moderate COVID infection.
Hear when a new Persistent Postural Perceptual Dizziness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.